Search results for " Diabete"

showing 10 items of 2949 documents

Glycolysis Metabolites and Risk of Atrial Fibrillation and Heart Failure in the PREDIMED Trial

2021

The increased prevalence of atrial fibrillation (AF) and heart failure (HF) highlights the need to better understand the mechanisms underlying these cardiovascular diseases (CVDs). In the present study, we aimed to evaluate the association between glycolysis-related metabolites and the risk of AF and HF in a Mediterranean population at high risk of CVD. We used two case-control studies nested within the PREDIMED trial. A total of 512 incident AF cases matched to 734 controls, and 334 incident HF cases matched to 508 controls, were included. Plasma metabolites were quantified by using hydrophilic interaction liquid chromatography coupled with high-resolution negative ion mode MS detection. C…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismPopulationheart failureHeart failure030204 cardiovascular system & hematologyBiochemistryMicrobiologyPathogenesis03 medical and health sciences0302 clinical medicineInternal medicinemedicineGlycolysisatrial fibrillation030212 general & internal medicineeducationMolecular Biologyeducation.field_of_studybusiness.industryBrief ReportAtrial fibrillationPREDIMED studyglycolysismedicine.diseasePredimedAtrial fibrillationQR1-502Increased riskHeart failureCardiologyConditional logistic regressionbusinessGlycolysis
researchProduct

Emerging therapies for raising high-density lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionality.

2014

High-density lipoprotein (HDL) particles are highly complex polymolecular aggregates capable of performing a remarkable range of atheroprotective functions. Considerable research is being performed throughout the world to develop novel pharmacologic approaches to: (1) promote apoprotein A-I and HDL particle biosynthesis; (2) augment capacity for reverse cholesterol transport so as to reduce risk for the development and progression of atherosclerotic disease; and (3) modulate the functionality of HDL particles in order to increase their capacity to antagonize oxidation, inflammation, thrombosis, endothelial dysfunction, insulin resistance, and other processes that participate in arterial wal…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismRVX 208BiologyBioinformaticschemistry.chemical_compoundEndocrinologyInsulin resistanceHigh-density lipoproteinInternal medicinemedicineHumansEndothelial dysfunctionLiver X receptorDyslipidemiasTherapies InvestigationalReverse cholesterol transportCholesterol HDLGenetic Therapymedicine.diseaseUp-RegulationEndocrinologychemistryCardiovascular Diseaseslipids (amino acids peptides and proteins)Farnesoid X receptorLipoproteinBest practiceresearch. Clinical endocrinologymetabolism
researchProduct

From obesity to Alzheimer's disease through insulin resistance

2021

Alzheimer's disease is one of the most frequent forms of dementia. It is a progressive neurodegenerative disease, characterized by presence of amyloid plaques and neurofibrillary tangles in the brain. Obesity is regarded as abnormal fat accumulation with deleterious impact on human health. There is full scientific evidence that obesity and the metabolic comorbidities (e.g., insulin resistance, hyperglycaemia, and type 2 diabetes) are related to Alzheimer's disease and likely in the causative pathway. Numerous studies have identified several overlapping neurodegenerative mechanisms, including oxidative stress, mitochondrial dysfunction, and inflammation. In this review, we present how obesit…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismType 2 diabetesmedicine.disease_causeEndocrinologyInsulin resistanceDownregulation and upregulationAlzheimer DiseaseInternal medicineDiabetes mellitusInternal MedicinemedicineHumansDementiaObesityNeurodegenerationInflammationbusiness.industryNeurodegenerationBrainInsulin resistanceAlzheimer's diseasemedicine.diseaseEndocrinologyDiabetes Mellitus Type 2LipotoxicitybusinessOxidative stressJournal of Diabetes and its Complications
researchProduct

Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis

2015

Outcomes from 5 years of treatment with agalsidase alfa enzyme replacement therapy (ERT) for Fabry disease in patients enrolled in the Fabry Outcome Survey (FOS) were compared with published findings for untreated patients with Fabry disease. Data were extracted from FOS, a Shire-sponsored database, for comparison with data from three published studies. Outcomes evaluated were the annualized rate of change in estimated glomerular filtration rate (eGFR) and left ventricular mass indexed to height (LVMI) as well as time to and ages at a composite morbidity endpoint and at death. FOS data were extracted for 740 treated patients who were followed for a median of ~ 5 years. Compared with no trea…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismUrologyCardiomyopathyRenal functionSE Standard errorLeft ventricular hypertrophyBiochemistryLVH Left ventricular hypertrophyLong-term effectivenessEndocrinologyGeneticsMedicineMDRD Modification of Diet in Renal Diseaselcsh:QH301-705.5Molecular BiologyAgalsidase alfaeGFR Estimated glomerular filtration rateFabry diseaselcsh:R5-920CI Confidence intervalbusiness.industryEnzyme replacement therapymedicine.diseaseEgfr Estimated glomerular filtration rateFabry diseaseSurgeryARB Angiotensin receptor blockerSEM Standard error of the meanStandard errorlcsh:Biology (General)SI:TherapyEnzyme replacement therapyCohortFOS Fabry Outcome SurveyLVMI Left ventricular mass indexed to heightlcsh:Medicine (General)businessACEI Angiotensin-converting enzyme inhibitorAgalsidase alfaERT Enzyme replacement therapyMolecular Genetics and Metabolism Reports
researchProduct

Proteinuria-Lowering Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Chronic Kidney Disease Patients: A Real-World Multicentri…

2021

Control of dyslipidemia in chronic kidney disease (CKD) is not always guaranteed with statins and/or ezetimibe. Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) have opened up a new era in lipid control, but their effect on renal function and proteinuria in real life have not yet been evaluated. The aim of the present study was to analyze the evolution of renal function and proteinuria in a cohort of CKD patients treated with PCSK9i. This retrospective multicentric cohort study included CKD patients treated with PCSK9i. Baseline epidemiological data, comorbidities and laboratory findings (including estimated glomerular filtration rate [eGFR], proteinuria and lipid profile) …

medicine.medical_specialtyEndocrinology Diabetes and MetabolismUrologyRenal functionurologic and male genital diseasesMicrobiologyBiochemistryArticleNephrotoxicitychemistry.chemical_compoundEzetimibePCSK9iCKDmedicinekidney functionMolecular BiologyCreatinineProteinuriamedicine.diagnostic_testbusiness.industrymedicine.diseaseQR1-502female genital diseases and pregnancy complicationschemistryInsuficiència renal crònicaproteinuriamedicine.symptomLipid profilebusinessDyslipidemiaKidney diseasemedicine.drugMetabolites
researchProduct

Wine consumption and renal diseases: new perspectives.

2006

Investigations into the relation between wine consumption and kidney disease have been limited. Patients with chronic renal failure show accelerated atherosclerotic damage and, considering the well-known protective effect of wine on the cardiovascular system, moderate wine consumption might be advantageous. Oxidative stress and endothelial dysfunction, which are inter-related, play a role in the pathophysiology of many renal diseases, including acute and chronic renal failure. Ethanol and non-alcoholic wine components, especially polyphenols, influence oxidative balance and endothelial function. Although long-term alcohol abuse has been associated with many renal alterations in humans, in e…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismWinePharmacologyKidneyAntioxidantsNephropathyDiabetic nephropathyPhenolsInternal medicinemedicineHumansEndothelial dysfunctionFlavonoidsWineKidneyNutrition and DieteticsRenal ischemiabusiness.industryPolyphenolsfood and beveragesKidney metabolismmedicine.diseaseOxidative Stressmedicine.anatomical_structureEndocrinologyKidney Failure ChronicEndothelium VascularbusinessOxidation-ReductionKidney disease
researchProduct

Polyunsaturated n-3 and n-6 fatty acids at a low level in the diet alter mitochondrial outer membrane parameters in Wistar rat liver

1995

Abstract This study was designed to examine whether n-3 and n-6 polyunsaturated fatty acids (PUFA) at a very low level in the diet (about 0.2%) may alter the fatty acid composition of mitochondrial outer membranes and the characteristics of carnitine palmitoyltransferase I (CPTI) activity in the liver of normal Wistar rats. The animals were fed diets containing different oil mixtures (5% wt/wt) with the same ratio of n-6 n-3 fatty acids supplied either as fish oil or arachidonic acid concentrate. The cholesterol content of the mitochondrial outer membranes from liver was similar for all diets, while the percentage of 22:6n-3 and 20:4n-6 in phospholipids was enhanced with the diets containin…

medicine.medical_specialtyEndocrinology Diabetes and Metabolism[SDV]Life Sciences [q-bio]Clinical BiochemistryMitochondrionBiologyBiochemistry03 medical and health scienceschemistry.chemical_compoundInternal medicinemedicineCarnitine O-palmitoyltransferaseMolecular BiologyComputingMilieux_MISCELLANEOUS030304 developmental biology2. Zero hungerchemistry.chemical_classification0303 health sciencesNutrition and DieteticsCholesterol030302 biochemistry & molecular biologyMetabolismFish oilEndocrinologyBiochemistrychemistrylipids (amino acids peptides and proteins)Arachidonic acidCarnitine palmitoyltransferase IPolyunsaturated fatty acid
researchProduct

Chronic Kidney Disease, Diabetes, and Risk of Mortality After Acute Myocardial Infarction: Insight From the FAST-MI Program

2020

Diabetes is associated with a substantially increased risk of all-cause death, mainly driven by cardiovascular (CV) mortality. Furthermore, diabetes is associated with poorer outcomes after acute myocardial infarction (AMI) (1). Impaired glomerular filtration rate (GFR) is also associated with an increased risk of CV mortality (2). However, whether diabetes still confers a higher risk of mortality in patients with impaired GFR remains unknown. The aim of this study was to assess the long-term prognostic significance of both diabetes and renal impairment in two prospective nationwide cohorts of AMI patients: FAST-MI (French Registry of Acute ST-Elevation or non-ST-elevation Myocardial Infarc…

medicine.medical_specialtyEndocrinology Diabetes and Metabolism[SDV]Life Sciences [q-bio]Renal function030209 endocrinology & metabolism03 medical and health sciences0302 clinical medicineInternal medicineDiabetes mellitusIntensive careInternal MedicinemedicineRisk of mortality030212 general & internal medicineMyocardial infarction10. No inequalityComputingMilieux_MISCELLANEOUSAdvanced and Specialized NursingFramingham Risk Scorebusiness.industrymedicine.disease3. Good healthHeart failureCardiologybusinessKidney disease
researchProduct

Uterine Receptivity and the Ramifications of Ovarian Stimulation on Endometrial Function

2007

Controlled ovarian stimulation (COS) is widely used in assisted reproduction techniques (ART). However, hormonal treatment induces endometrial alterations that may alter implantation rates compared with natural cycles. Endometrial alterations have been observed by histological and biochemical techniques. The recent developments in functional genomics have provided objective tools to analyze the endometrium in natural cycles and evaluate the impact of COS protocols in endometrial development. This article describes the fundamental aspects of endometrial receptivity in natural cycles and reports how COS affects the morphology, biochemistry, and the genomic pattern of the endometrium.

medicine.medical_specialtyEndocrinology Diabetes and Metabolismmedia_common.quotation_subjectUterusOvaryStimulationBiologyEndometriumAndrologyEndometriumEndocrinologyOvulation InductionPregnancyPhysiology (medical)Internal medicinemedicineHumansEmbryo ImplantationMenstrual CycleMenstrual cycleOligonucleotide Array Sequence Analysismedia_commonPrincipal Component AnalysisGene Expression ProfilingGene Expression Regulation DevelopmentalObstetrics and GynecologyGenomicsEndocrinologymedicine.anatomical_structureReproductive MedicineIn uteroFemaleFunction (biology)HormoneSeminars in Reproductive Medicine
researchProduct

Liraglutide Improves Cardiovascular Risk as an Add-on to Metformin and Not to Insulin Secretagogues in Type 2 Diabetic Patients: A Real-life 48-Month…

2017

INTRODUCTION: Although liraglutide is widely recognized to have glycemic and extra-glycemic effects, few studies have compared these effects in relation to hypoglycemic treatment starting from the diagnosis of diabetes. We evaluated the effectiveness of liraglutide in reducing the Framingham risk score (FRS) and visceral adiposity index (VAI) in relation to first-line hypoglycemic treatment from diagnosis of type 2 diabetes, continued without any changes. METHODS: We selected 105 diabetic outpatients who were treated with liraglutide for at least 48 months as an add-on therapy to metformin alone (group A, n = 52) or insulin secretagogues (group B, n = 53) from diagnosis time. RESULTS: Altho…

medicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatment030209 endocrinology & metabolismType 2 diabetes030204 cardiovascular system & hematologyGastroenterologySettore MED/13 - Endocrinologia03 medical and health sciences0302 clinical medicineDiabetes mellitusInternal medicineInternal MedicinemedicineGlycemicFramingham Risk Scorebusiness.industryLiraglutideBrief ReportInsulinDiabetesLiraglutideCardiovascular riskmedicine.diseaseliraglutide diabetesMetforminEndocrinologyBlood pressureVisceral adipositybusinessmedicine.drug
researchProduct